Management of behavioral and psychiatric problems in Parkinson's disease

Alejandro Rabinstein, L. M. Shulman

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Behavioral and psychiatric problems associated with idiopathic Parkinson's disease (PD) include cognitive dysfunction, drug-related psychosis, depression, anxiety, apathy, fatigue and sleep disturbance. These nonmotor symptoms are a significant cause of disability at all stages of illness. Cognitive dysfunction spans a continuum from circumscribed cognitive impairments to severe global dementia which can occur in up to 10-30% of advanced PD patients. Psychosis develops in 20-30% of PD patients receiving chronic antiparkinsonian therapy. Visual hallucinations and paranoid delusions are the most frequent symptoms. The gradual elimination of drugs of lesser priority that may affect cognition and/or cloud the sensorium constitutes the first step in the management of cognitive and psychotic symptoms. Atypical neuroleptic agents are an invaluable tool in those cases in which maximum drug regimen simplification is not adequate or results in unacceptable immobility. Depression and anxiety often go unrecognized although they are eminently treatable and may be important contributors to the morbidity of PD. They are present in 30-40% of PD patients and frequently occur together in association with other nonmotor symptoms such as apathy, fatigue and sleep disturbance. A combination of early recognition, counseling, antidepressant therapy, antianxiety and well-balanced antiparkinsonian therapy sets the stage for improved quality of life for patients with PD. (C) 2000 Published by Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)41-50
Number of pages10
JournalParkinsonism and Related Disorders
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Parkinson Disease
Psychiatry
Antiparkinson Agents
Apathy
Fatigue
Sleep
Anxiety
Substance-Induced Psychoses
Depression
Neurobehavioral Manifestations
Delusions
Hallucinations
Pharmaceutical Preparations
Psychotic Disorders
Cognition
Antidepressive Agents
Antipsychotic Agents
Dementia
Problem Behavior
Counseling

Keywords

  • Anxiety
  • Cognitive dysfunction
  • Depression
  • Idiopathic Parkinson's disease
  • PD related psychosis

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Management of behavioral and psychiatric problems in Parkinson's disease. / Rabinstein, Alejandro; Shulman, L. M.

In: Parkinsonism and Related Disorders, Vol. 7, No. 1, 01.01.2000, p. 41-50.

Research output: Contribution to journalReview article

@article{3c855d87216f4716b6bdff583db0c311,
title = "Management of behavioral and psychiatric problems in Parkinson's disease",
abstract = "Behavioral and psychiatric problems associated with idiopathic Parkinson's disease (PD) include cognitive dysfunction, drug-related psychosis, depression, anxiety, apathy, fatigue and sleep disturbance. These nonmotor symptoms are a significant cause of disability at all stages of illness. Cognitive dysfunction spans a continuum from circumscribed cognitive impairments to severe global dementia which can occur in up to 10-30{\%} of advanced PD patients. Psychosis develops in 20-30{\%} of PD patients receiving chronic antiparkinsonian therapy. Visual hallucinations and paranoid delusions are the most frequent symptoms. The gradual elimination of drugs of lesser priority that may affect cognition and/or cloud the sensorium constitutes the first step in the management of cognitive and psychotic symptoms. Atypical neuroleptic agents are an invaluable tool in those cases in which maximum drug regimen simplification is not adequate or results in unacceptable immobility. Depression and anxiety often go unrecognized although they are eminently treatable and may be important contributors to the morbidity of PD. They are present in 30-40{\%} of PD patients and frequently occur together in association with other nonmotor symptoms such as apathy, fatigue and sleep disturbance. A combination of early recognition, counseling, antidepressant therapy, antianxiety and well-balanced antiparkinsonian therapy sets the stage for improved quality of life for patients with PD. (C) 2000 Published by Elsevier Science Ltd.",
keywords = "Anxiety, Cognitive dysfunction, Depression, Idiopathic Parkinson's disease, PD related psychosis",
author = "Alejandro Rabinstein and Shulman, {L. M.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1353-8020(00)00039-0",
language = "English (US)",
volume = "7",
pages = "41--50",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Management of behavioral and psychiatric problems in Parkinson's disease

AU - Rabinstein, Alejandro

AU - Shulman, L. M.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Behavioral and psychiatric problems associated with idiopathic Parkinson's disease (PD) include cognitive dysfunction, drug-related psychosis, depression, anxiety, apathy, fatigue and sleep disturbance. These nonmotor symptoms are a significant cause of disability at all stages of illness. Cognitive dysfunction spans a continuum from circumscribed cognitive impairments to severe global dementia which can occur in up to 10-30% of advanced PD patients. Psychosis develops in 20-30% of PD patients receiving chronic antiparkinsonian therapy. Visual hallucinations and paranoid delusions are the most frequent symptoms. The gradual elimination of drugs of lesser priority that may affect cognition and/or cloud the sensorium constitutes the first step in the management of cognitive and psychotic symptoms. Atypical neuroleptic agents are an invaluable tool in those cases in which maximum drug regimen simplification is not adequate or results in unacceptable immobility. Depression and anxiety often go unrecognized although they are eminently treatable and may be important contributors to the morbidity of PD. They are present in 30-40% of PD patients and frequently occur together in association with other nonmotor symptoms such as apathy, fatigue and sleep disturbance. A combination of early recognition, counseling, antidepressant therapy, antianxiety and well-balanced antiparkinsonian therapy sets the stage for improved quality of life for patients with PD. (C) 2000 Published by Elsevier Science Ltd.

AB - Behavioral and psychiatric problems associated with idiopathic Parkinson's disease (PD) include cognitive dysfunction, drug-related psychosis, depression, anxiety, apathy, fatigue and sleep disturbance. These nonmotor symptoms are a significant cause of disability at all stages of illness. Cognitive dysfunction spans a continuum from circumscribed cognitive impairments to severe global dementia which can occur in up to 10-30% of advanced PD patients. Psychosis develops in 20-30% of PD patients receiving chronic antiparkinsonian therapy. Visual hallucinations and paranoid delusions are the most frequent symptoms. The gradual elimination of drugs of lesser priority that may affect cognition and/or cloud the sensorium constitutes the first step in the management of cognitive and psychotic symptoms. Atypical neuroleptic agents are an invaluable tool in those cases in which maximum drug regimen simplification is not adequate or results in unacceptable immobility. Depression and anxiety often go unrecognized although they are eminently treatable and may be important contributors to the morbidity of PD. They are present in 30-40% of PD patients and frequently occur together in association with other nonmotor symptoms such as apathy, fatigue and sleep disturbance. A combination of early recognition, counseling, antidepressant therapy, antianxiety and well-balanced antiparkinsonian therapy sets the stage for improved quality of life for patients with PD. (C) 2000 Published by Elsevier Science Ltd.

KW - Anxiety

KW - Cognitive dysfunction

KW - Depression

KW - Idiopathic Parkinson's disease

KW - PD related psychosis

UR - http://www.scopus.com/inward/record.url?scp=0033805755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033805755&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(00)00039-0

DO - 10.1016/S1353-8020(00)00039-0

M3 - Review article

VL - 7

SP - 41

EP - 50

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 1

ER -